C-reactive protein reduction post treatment is associated with improved survival in atezolizumab (anti-PD-L1) treated non-small cell lung cancer patients
Fig 2
CRP ratios relative to pre-treatment is associated with overall response post-atezolizumab treatment but not with docetaxel treatment in the POPLAR and OAK studies.
CRP log 2 ratio relative to pre-treatment or C1D1 pre-dose for each patient for each treatment arm for the first four visits with dotted lines marking an increase (1.5 fold increase) or decreased (1.5 fold decrease) relative to pre-treatment. CR, complete response; CRP, c-reactive protein; PD, disease progression; PR, partial response; RECIST v1.1, Response Evaluation Criteria in Solid Tumors version 1.1; SD, stable disease.